<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35072299</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1360-0443</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>117</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Addiction (Abingdon, England)</Title>
          <ISOAbbreviation>Addiction</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Ongoing HIV transmission following a large outbreak among people who inject drugs in Athens, Greece (2014-20).</ArticleTitle>
        <Pagination>
          <StartPage>1670</StartPage>
          <EndPage>1682</EndPage>
          <MedlinePgn>1670-1682</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/add.15812</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">The human immunodeficiency virus (HIV) outbreak among people who inject drugs (PWID) in Athens, Greece in 2011-13 was the largest recent epidemic in Europe and North America. We aimed to assess trends in HIV prevalence, drug use and access to prevention among PWID in Athens to estimate HIV incidence and identify risk factors and to explore HIV-1 dispersal using molecular methods during 2014-20.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Two community-based HIV/hepatitis C programmes on PWID were implemented in 2012-13 (n = 3320) and 2018-20 (n = 1635) through consecutive respondent-driven sampling (RDS) rounds. PWID were uniquely identified among rounds/programmes. We obtained RDS-weighted HIV prevalence estimates per round for 2018-20 and compared them to 2012-13. We assessed changes in HIV status, behaviours and access to prevention in PWID participating in both periods. We estimated HIV incidence in a cohort of seronegative PWID as the number of HIV seroconversions/100 person-years during 2014-20 and used Cox regression to identify associated risk factors. Molecular sequencing and phylogenetic analysis were performed in HIV seroconverters.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">HIV prevalence per round ranged between 12.0 and 16.2% in 2012-13 and 10.7 and 11.3% in 2018-20 with overlapping 95% confidence intervals (95% CI). Among PWID participating in both programmes, HIV prevalence (95% CI) increased from 14.2% (11.7-17.1%) in 2012-13 to 22.0% (19.0-25.3%) in 2018-20 (P &lt; 0.001). There was a deterioration in socio-economic characteristics such as homelessness [from 16.2% (95% CI = 13.5-19.2%) to 25.6% (22.3-29.0%)], a shift in cocaine use [16.6% (13.9-19.6%) versus 28.1% (24.7-31.7%], reduced access to free syringes [51.8% (48.0-55.7%) versus 44.5% (40.7-48.3%)] and a decrease in daily injecting [36.2% (32.6-39.9%) versus 28.5% (25.2-32.1%)]. HIV incidence (95% CI) in 2014-20 was 1.94 (1.50-2.52) new cases/100 person-years and younger age, lower educational level, larger injection network and daily injecting were risk factors. Almost 9% of HIV seroconversions occurred within a newly expanding phylogenetic cluster.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In Athens, Greece, compared with the period 2012-13, in the period 2018-20 there was a deterioration in socio-economic conditions among people who inject drugs, an increase in the use of cocaine, reduced access to needle and syringe programmes and stable low levels of human immunodeficiency virus testing. Ongoing human immunodeficiency virus transmission was documented during 2014-20 in existing as well as new transmission clusters.</AbstractText>
          <CopyrightInformation>© 2022 Society for the Study of Addiction.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Roussos</LastName>
            <ForeName>Sotirios</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0003-2347-0817</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paraskevis</LastName>
            <ForeName>Dimitrios</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Psichogiou</LastName>
            <ForeName>Mina</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kostaki</LastName>
            <ForeName>Evangelia Georgia</ForeName>
            <Initials>EG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Flountzi</LastName>
            <ForeName>Eleni</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angelopoulos</LastName>
            <ForeName>Theodoros</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chaikalis</LastName>
            <ForeName>Savvas</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Papadopoulou</LastName>
            <ForeName>Martha</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, Athens, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pavlopoulou</LastName>
            <ForeName>Ioanna D</ForeName>
            <Initials>ID</Initials>
            <AffiliationInfo>
              <Affiliation>Pediatric Research Laboratory, Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Malliori</LastName>
            <ForeName>Meni</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Psychiatric Department, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatzitheodorou</LastName>
            <ForeName>Eleni</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic National Public Health Organization, Marousi, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pylli</LastName>
            <ForeName>Magdalini</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic National Public Health Organization, Marousi, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsiara</LastName>
            <ForeName>Chrissa</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic National Public Health Organization, Marousi, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paraskeva</LastName>
            <ForeName>Dimitra</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic National Public Health Organization, Marousi, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Beloukas</LastName>
            <ForeName>Apostolos</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-5639-0528</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Sciences, University of West Attica, Athens, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kalamitsis</LastName>
            <ForeName>George</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Hellenic Liver Patient Association 'Prometheus', Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hatzakis</LastName>
            <ForeName>Angelos</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Hellenic Scientific Society for the Study of AIDS, STDs and Emerging Diseases, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sypsa</LastName>
            <ForeName>Vana</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0002-9430-7614</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Addiction</MedlineTA>
        <NlmUniqueID>9304118</NlmUniqueID>
        <ISSNLinking>0965-2140</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>I5Y540LHVR</RegistryNumber>
          <NameOfSubstance UI="D003042">Cocaine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003042" MajorTopicYN="Y">Cocaine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055030" MajorTopicYN="Y">Drug Users</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006679" MajorTopicYN="Y">HIV Seropositivity</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012309" MajorTopicYN="N">Risk-Taking</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015819" MajorTopicYN="Y">Substance Abuse, Intravenous</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Greece</Keyword>
        <Keyword MajorTopicYN="N">HIV</Keyword>
        <Keyword MajorTopicYN="N">PWID</Keyword>
        <Keyword MajorTopicYN="N">incidence</Keyword>
        <Keyword MajorTopicYN="N">outbreak</Keyword>
        <Keyword MajorTopicYN="N">phylogenetics</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>8</Hour>
          <Minute>59</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35072299</ArticleId>
        <ArticleId IdType="doi">10.1111/add.15812</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5:e1192-207.</Citation>
        </Reference>
        <Reference>
          <Citation>Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: Ending old epidemics and addressing new outbreaks. Aids. 2016;30:815-26.</Citation>
        </Reference>
        <Reference>
          <Citation>Des Jarlais DC, Sypsa V, Feelemyer J, Abagiu AO, Arendt V, Broz D, et al. HIV outbreaks among people who inject drugs in Europe, North America, and Israel. Lancet HIV. 2020;7:e434-42.</Citation>
        </Reference>
        <Reference>
          <Citation>Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, et al. Rapid decline in HIV incidence among persons who inject drugs during a fast-track combination prevention program after an HIV outbreak in Athens. J Infect Dis. 2017;215:1496-505.</Citation>
        </Reference>
        <Reference>
          <Citation>Paraskevis D, Nikolopoulos G, Fotiou A, Tsiara C, Paraskeva D, Sypsa V, et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLOS ONE. 2013;8:e78941.</Citation>
        </Reference>
        <Reference>
          <Citation>Malliori M, Golna C, Souliotis K, Hatzakis A. Financial crisis, austerity, and health in Europe. Lancet. 2013;382:392.</Citation>
        </Reference>
        <Reference>
          <Citation>Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, et al. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015;110:1453-67.</Citation>
        </Reference>
        <Reference>
          <Citation>National Public Health Organization. HIV/AIDS Surveillance Report in Greece, 31-12-2019 (issue 34). Athens, Greece: National Public Health Organization; 2020. Available at: https://eody.gov.gr. Accessed 25 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Greek National Documentation and Information Centre on Drugs and Drug Addiction. Annual Report on the State of Drugs and Alcohol in Greece 2019. Athens, Greece: Greek National Documentation and Information Centre on Drugs and Drug Addiction; 2020 [in Greek].</Citation>
        </Reference>
        <Reference>
          <Citation>Heckathorn D. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44:174-99.</Citation>
        </Reference>
        <Reference>
          <Citation>Volz E, Wejnert C, Cameron C, Spiller M, Barash V, Degani I, et al. Respondent-driven Sampling Analysis Tool (RDSAT) Version 7.1. Ithaca, NY: Cornell University; 2012.</Citation>
        </Reference>
        <Reference>
          <Citation>Gallagher KM, Sullivan PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk for HIV infection in the U.S.: the national HIV behavioral surveillance system. Public Health Rep. 2007;122:32-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Vandormael A, Dobra A, Barnighausen T, de Oliveira T, Tanser F. Incidence rate estimation, periodic testing and the limitations of the mid-point imputation approach. Int J Epidemiol. 2018;47:236-45.</Citation>
        </Reference>
        <Reference>
          <Citation>Kasamba I, Nash S, Seeley J, Weiss HA. HIV incidence among women at high risk of HIV infection attending a dedicated clinic in Kampala, Uganda: 2008-2017. Sex Transm Dis. 2019;46:407-15.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin M, Vanichseni S, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, et al. HIV incidence and risk behaviours of people who inject drugs in Bangkok, 1995-2012. eClinMed. 2019;9:44-51. Accessed 25 May 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Struck D, Lawyer G, Ternes A-M, Schmit J-C, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42:e144-4.</Citation>
        </Reference>
        <Reference>
          <Citation>Kostaki E, Magiorkinis G, Psichogiou M, Flampouris A, Iliopoulos P, Papachristou E, et al. Detailed molecular surveillance of the HIV-1 outbreak among people who inject drugs (PWID) in Athens during a period of four years. Curr HIV Res. 2017;15:396-404.</Citation>
        </Reference>
        <Reference>
          <Citation>Price MN, Dehal PS, Arkin AP. FastTree 2-approximately maximum-likelihood trees for large alignments. PLOS ONE. 2010;5:e9490.</Citation>
        </Reference>
        <Reference>
          <Citation>Paraskevis D, Kostaki E, Magiorkinis G, Gargalianos P, Xylomenos G, Magiorkinis E, et al. Prevalence of drug resistance among HIV-1 treatment-naive patients in Greece during 2003-2015: transmitted drug resistance is due to onward transmissions. Infect Genet Evol. 2017;54:183-91.</Citation>
        </Reference>
        <Reference>
          <Citation>Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P. RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics. 2010;26:2462-3.</Citation>
        </Reference>
        <Reference>
          <Citation>Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73:152-60.</Citation>
        </Reference>
        <Reference>
          <Citation>Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-26.</Citation>
        </Reference>
        <Reference>
          <Citation>Collett D. Modelling Survival data In Medical Research. Boca Raton, FL: CRC Press; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp; 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6:e315-24.</Citation>
        </Reference>
        <Reference>
          <Citation>Arendt V, Guillorit L, Origer A, Sauvageot N, Vaillant M, Fischer A, et al. Injection of cocaine is associated with a recent HIV outbreak in people who inject drugs in Luxembourg. PLOS ONE. 2019;14:e0215570.</Citation>
        </Reference>
        <Reference>
          <Citation>Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. Aids. 2003;17:887-93.</Citation>
        </Reference>
        <Reference>
          <Citation>Sax H, Allegranzi B, Chraiti MN, Boyce J, Larson E, Pittet D. The World Health Organization hand hygiene observation method. Am J Infect Control. 2009;37:827-34.</Citation>
        </Reference>
        <Reference>
          <Citation>Bobkov A, Cheingsong-Popov R, Selimova L, Ladnaya N, Kazennova E, Kravchenko A, et al. An HIV type 1 epidemic among injecting drug users in the former Soviet Union caused by a homogeneous subtype A strain. AIDS Res Hum Retroviruses. 1997;13:1195-201.</Citation>
        </Reference>
        <Reference>
          <Citation>Kirichenko A, Lapovok I, Baryshev P, van de Vijver DA, van Kampen JJ, Boucher CA, et al. Genetic features of HIV-1 integrase sub-subtype A6 predominant in Russia and predicted susceptibility to INSTIs. Viruses. 2020;12:838.</Citation>
        </Reference>
        <Reference>
          <Citation>Lebedev A, Lebedeva N, Moskaleychik F, Pronin A, Kazennova E, Bobkova M. Human immunodeficiency virus-1 diversity in the Moscow region, Russia: phylodynamics of the most common subtypes. Front Microbiol. 2019;10:320.</Citation>
        </Reference>
        <Reference>
          <Citation>Strathdee SA, Galai N, Safaiean M, Celentano DD, Vlahov D, Johnson L, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med. 2001;161:1281-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Sharifi H, Mirzazadeh A, Shokoohi M, Karamouzian M, Khajehkazemi R, Navadeh S, et al. Estimation of HIV incidence and its trend in three key populations in Iran. PLOS ONE. 2018;13:e0207681.</Citation>
        </Reference>
        <Reference>
          <Citation>Ganapathi L, McFall AM, Srikrishnan AK, Kumar MS, Anand S, Lucas GM, et al. Young people who inject drugs in India have high HIV incidence and behavioural risk: a cross-sectional study. J Int AIDS Soc. 2019;22:e25287.</Citation>
        </Reference>
        <Reference>
          <Citation>Scheim AI, Nosova E, Knight R, Hayashi K, Kerr T. HIV incidence among men who have sex with men and inject drugs in a Canadian setting. AIDS Behav. 2018;22:3957-61.</Citation>
        </Reference>
        <Reference>
          <Citation>Jolley E, Rhodes T, Platt L, Hope V, Latypov A, Donoghoe M, et al. HIV among people who inject drugs in central and Eastern Europe and Central Asia: a systematic review with implications for policy. BMJ Open. 2012;2:e001465.</Citation>
        </Reference>
        <Reference>
          <Citation>Richardson L, Mammel M, Milloy MJ, Hayashi K. Employment cessation, long term labour market engagement and HIV infection risk among people who inject drugs in an urban Canadian setting. AIDS Behav. 2019;23:3267-76.</Citation>
        </Reference>
        <Reference>
          <Citation>Czerwinski M, McNutt LA, DeHovitz JA, Zielinski A, Rosinska M. Refining HIV risk: the modifying effects of youth, gender and education among people who inject drugs in Poland. PLOS ONE. 2013;8:e68018.</Citation>
        </Reference>
        <Reference>
          <Citation>Mburu G, Chhoun P, Chann N, Tuot S, Mun P, Yi S. Prevalence and risk factors of HIV infection among people who inject drugs in Cambodia: findings from a national survey. Subst Abuse Treat Prev Policy. 2019;14:42.</Citation>
        </Reference>
        <Reference>
          <Citation>Des Jarlais DC, Huong DT, Oanh KTH, Feelemyer JP, Arasteh K, Khue PM, et al. Ending an HIV epidemic among persons who inject drugs in a middle-income country: Extremely low HIV incidence among persons who inject drugs in Hai Phong, Viet Nam. Aids. 2020;34:2305-11.</Citation>
        </Reference>
        <Reference>
          <Citation>Vourli G, Nikolopoulos G, Paparizos V, Skoutelis A, Metallidis S, Gargalianos P, et al. HIV cascade of care in Greece: useful insights from additional stages. PLOS ONE. 2018;13:e0207355.</Citation>
        </Reference>
        <Reference>
          <Citation>Greek National Monitoring and Documentation Center for Drugs and Drug Addiction. Annual Report on the State of Drugs and Alcohol in Greece 2019. Athens, Greece: Greek National Monitoring and Documentation Center for Drugs and Drug Addiction; 2020 [in Greek].</Citation>
        </Reference>
        <Reference>
          <Citation>Greek National Monitoring and Documentation Center for Drugs and Drug Addiction. Annual Report on the State of Drugs and Alcohol in Greece 2013. Athens, Greece: Greek National Monitoring and Documentation Center for Drugs and Drug Addiction; 2014 [in Greek].</Citation>
        </Reference>
        <Reference>
          <Citation>Nikolopoulos GK, Katsoulidou A, Kantzanou M, Rokka C, Tsiara C, Sypsa V, et al. Evaluation of the limiting antigen avidity EIA (LAg) in people who inject drugs in Greece. Epidemiol Infect. 2017;145:401-12.</Citation>
        </Reference>
        <Reference>
          <Citation>Wiessing L, Sypsa V, Arendt V, Bosch A, Buskin S, Carlson D et al. Impact of COVID-19 on services for people who inject drugs in sites with recent HIV outbreaks in Europe, North America and Israel; 23rd International AIDS Conference; 2020. Available at: http://programme.aids2020.org/Abstract/Abstract/11215. Accessed 25 May 2021.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
